Spirit Pharmaceuticals Llc Pharmaceutical Import Profile — United States (DGFT 2022–2026)

Name: Spirit Pharmaceuticals Llc Pharmaceutical Import Records from India — 7 Products, $44.7M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Spirit Pharmaceuticals Llc — Pharmaceutical Importer Profile (2026) | 7 Products, $44.7M Trade | TransData Nexus

Spirit Pharmaceuticals Llc

Pharmaceutical Importer · United States · Nutritional Supplements Focus · $44.7M Total Trade · DGFT Verified

Spirit Pharmaceuticals Llc is a pharmaceutical importer based in United States with a total trade value of $44.7M across 7 products in 5 therapeutic categories. Based on 908 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Spirit Pharmaceuticals Llc sources from 6 verified Indian suppliers, with Elysium Pharmaceuticals Limited accounting for 93.2% of imports.

Spirit Pharmaceuticals Llc — Import Portfolio & Supplier Network

Spirit Pharmaceuticals Llc import network — 7 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Spirit Pharmaceuticals Llc?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Elysium Pharmaceuticals Limited	$19.7M	506	93.2%
Strides Pharma Science Limited	$582.2K	12	2.8%
J B Chemicals And Pharmaceuticals Limited

What Formulations Does Spirit Pharmaceuticals Llc Import?

Formulation	Value	Ships
Acetaminophen tabs USP 500MG (s500)	$1.7M	36
Acetaminophen dextromethorphen	$1.5M	32
Acetaminophen guaifenesin	$816.5K	17
Diphenhydramine hcl 25MG tablets 's-4'	$733.1K	24
Diphenhydramine hcl 25MG tablets s-4	$697.8K	16
Acetaminophen TAB's USP 500MG (s500)	$671.8K	14
Acetaminophen and diphenhydramaine	$450.0K	9
Acetaminophen TAB's USP 500MG (s500) (annexure-a) as per	$344.0K	15
Acetaminophen tabs USP 500MG (s500) -	$312.9K	7
Acetaminophen tabs USP 500MG s500 annexure	$300.0K	6
Acetaminophen TAB's USP 500MG s500 annexure - a as per	$300.0K	6
Diphenhydramine hcl 25MG tablets s-4 (pink) (annexure-b) as per	$295.3K	9
Acetaminophen TAB's USP 500MG (s500) (annexure-a) as per	$290.8K	9
Acetaminophen tabs USP 500MG (s500)-	$280.1K	6
Acetaminophen and diphenhydramaine hcltablets 's525' (annexure-b) as per	$263.4K	6

Spirit Pharmaceuticals Llc imports 229 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 7 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Amino	Nutritional Supplements	$17.4M	347	4.0%	3
2	Acetaminophen	Analgesics & Antipyretics	$17.3M	345	5.5%	3
3	Diphenhydramine	Antihistamines & Allergy	$5.8M	129	13.6%	2
4	Guaifenesin	Respiratory & OTC	$2.0M	40	6.7%	2
5	Phenylephrine	Respiratory & OTC	$1.7M	34	2.0%	7
6	Dextromethorphan	Respiratory & OTC	$500.0K	10	3.4%	3
7	Docusate	Gastrointestinal	$96.0K	3	1.0%	13

Spirit Pharmaceuticals Llc imports 7 pharmaceutical products across 5 categories into United States totaling $44.7M.

Spirit Pharmaceuticals Llc — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Spirit Pharmaceuticals LLC is a privately held pharmaceutical company headquartered in Ronkonkoma, New York. Established in 2003, the company specializes in the innovation, development, manufacturing, and distribution of over-the-counter (OTC) pharmaceutical products. With a workforce of over 150 employees, Spirit Pharmaceuticals operates a 65,000-square-foot FDA-approved facility in Ronkonkoma, NY. The company's portfolio includes more than 100 OTC products across various dosage forms, with a focus on first-to-market and exclusive offerings.

In May 2025, Spirit Pharmaceuticals underwent a rebranding, changing its name to Prodose, Inc. This strategic move reflects the company's commitment to growth and adaptation in the evolving pharmaceutical landscape. As a pharmaceutical importer and buyer, Spirit Pharmaceuticals plays a significant role in the United States' pharmaceutical distribution network, sourcing a diverse range of products to meet market demands.

2Distribution Network

Spirit Pharmaceuticals' distribution network is centered around its FDA-approved facility in Ronkonkoma, New York. This strategic location enables efficient logistics and distribution across the United States. The company's operations are supported by a dedicated team of over 150 employees, ensuring streamlined processes from manufacturing to delivery. While specific details about additional warehouse locations and logistics capabilities are not publicly disclosed, the company's substantial facility size and workforce suggest a robust infrastructure capable of supporting extensive distribution needs.

3Industry Role

As a pharmaceutical importer and buyer, Spirit Pharmaceuticals LLC serves as a key player in the United States' pharmaceutical supply chain. The company sources a variety of pharmaceutical products, including over-the-counter medications, to meet the diverse needs of the U.S. market. By importing finished pharmaceutical formulations from international suppliers, Spirit Pharmaceuticals contributes to the availability and accessibility of a wide range of therapeutic options for consumers.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Spirit Pharmaceuticals Llc

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Spirit Pharmaceuticals demonstrates a high degree of sourcing concentration, with a significant portion of its imports originating from a single supplier, Elysium Pharmaceuticals Limited. Between 2022 and 2026, the company imported approximately $19.7 million worth of products from Elysium Pharmaceuticals, accounting for 93.2% of its total imports from India. This substantial reliance on a single supplier indicates a strategic partnership but also presents potential risks associated with supply chain disruptions.

The remaining imports are diversified among other suppliers, including Strides Pharma Science Limited, J B Chemicals and Pharmaceuticals Limited, and others. However, the dominance of Elysium Pharmaceuticals in Spirit Pharmaceuticals' sourcing strategy suggests a need for careful management of this relationship to mitigate potential risks.

2Supply Chain Resilience

The resilience of Spirit Pharmaceuticals' supply chain is closely tied to its reliance on Elysium Pharmaceuticals Limited. While this partnership offers stability and consistency in product quality, it also exposes the company to risks associated with potential disruptions at Elysium Pharmaceuticals. The limited number of backup suppliers and the concentration of imports in a single supplier highlight the need for Spirit Pharmaceuticals to develop contingency plans to address potential supply chain challenges.

Importing Pharmaceuticals into United States — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United States

1Regulatory Authority & Framework

In the United States, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing the importation of pharmaceutical products. The FDA ensures that all imported drugs meet the same standards for quality, safety, and effectiveness as domestically produced drugs. This includes reviewing shipments to determine their admissibility and conducting inspections to verify compliance with the Federal Food, Drug, and Cosmetic Act (FD&C Act).

Key legislation governing pharmaceutical imports includes the FD&C Act, which outlines the requirements for drug approval, labeling, and manufacturing practices. The FDA's Regulatory Procedures Manual provides detailed guidance on import operations and actions, including the process for detaining and refusing entry to violative products.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products entering the United States are governed by the FDA. Importers must file an entry notice and an entry bond with U.S. Customs and Border Protection, notifying the FDA of the product's arrival. The FDA reviews these entries to determine admissibility, ensuring that imported drugs comply with applicable legal and regulatory requirements.

Good Manufacturing Practice (GMP) certification is a critical component of the import process. The FDA requires that foreign manufacturers comply with GMP standards to ensure product quality and safety. While the FDA does not specifically recognize EU GMP, WHO GMP, or PIC/S certifications, compliance with these internationally recognized standards can facilitate the approval process for foreign manufacturers seeking to export to the U.S.

Spirit Pharmaceuticals Llc — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Spirit Pharmaceuticals' focus on importing products in the therapeutic categories of Nutritional Supplements, Analgesics & Antipyretics, and Antihistamines & Allergy reflects a strategic alignment with prevalent health concerns and consumer demands in the United States. The substantial import values in these categories indicate a strong market presence and a commitment to providing consumers with essential health products.

The market demand for these products is driven by factors such as an aging population, increased awareness of health and wellness, and a growing preference for self-medication. By concentrating on these therapeutic areas, Spirit Pharmaceuticals positions itself to meet the evolving needs of the U.S. healthcare market effectively.

2Sourcing Profile

Spirit Pharmaceuticals' sourcing strategy emphasizes importing finished pharmaceutical formulations from India, focusing on generic drugs. This approach allows the company to offer cost-effective alternatives to brand-name medications, catering to the price-sensitive segment of the U.S. market. The preference for finished formulations over active pharmaceutical ingredients (APIs) aligns with the company's goal of providing ready-to-market products that meet regulatory standards.

India's role as a major supplier of generic drugs to the U.S. market is well-established, with the country being a significant exporter of affordable therapeutics. By sourcing from India, Spirit Pharmaceuticals leverages the country's manufacturing capabilities and cost advantages to enhance its product offerings.

Seller's Guide — How to Become a Supplier to Spirit Pharmaceuticals Llc

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to enter Spirit Pharmaceuticals' supply chain. The company's reliance on a single supplier for a significant portion of its imports indicates potential for diversification. Indian exporters

TransData Nexus Research · Industry procurement practicesMar 2026

Frequently Asked Questions — Spirit Pharmaceuticals Llc

What products does Spirit Pharmaceuticals Llc import from India?

Spirit Pharmaceuticals Llc imports 7 pharmaceutical products across 5 categories. Top imports: Amino ($17.4M), Acetaminophen ($17.3M), Diphenhydramine ($5.8M), Guaifenesin ($2.0M), Phenylephrine ($1.7M).

Who supplies pharmaceuticals to Spirit Pharmaceuticals Llc from India?

Spirit Pharmaceuticals Llc sources from 6 verified Indian suppliers. The primary supplier is Elysium Pharmaceuticals Limited (93.2% of imports, $19.7M).

What is Spirit Pharmaceuticals Llc's total pharmaceutical import value?

Spirit Pharmaceuticals Llc's total pharmaceutical import value from India is $44.7M, based on 908 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Spirit Pharmaceuticals Llc focus on?

Spirit Pharmaceuticals Llc imports across 5 categories. The largest: Nutritional Supplements (38.8%), Analgesics & Antipyretics (38.6%), Antihistamines & Allergy (13.0%).

Get Full Spirit Pharmaceuticals Llc Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.